在COVID-19肝功能障碍患者中,雷梅西维尔的安全性和有效性:一项回顾性队列研究
Amirmohammad Sharafi1, Fatemeh Alsadat Mirzadeh2, Abolfazl Zendehdel3,4
1Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Journal of diabetes and metabolic disorders
|October 27, 2025
概括
在COVID-19患有肝功能障碍的患者中,雷梅西维尔治疗加速了临床康复. 这种抗病毒药物证明了安全性,在这个患者群体中,死亡率或严重不良事件没有显著增加.
科学领域:
- 传染性疾病 传染性疾病
- 肝病学 肝病学是一种肝病学.
- 临床药理学 临床药理学
背景情况:
- COVID-19患者经常出现肝功能障碍,使治疗决策复杂化.
- 在这种特定人群中,抗病毒疗法的安全性和有效性,如雷梅西维尔,需要进行彻底的调查.
研究的目的:
- 为了评估remdesivir在住院COVID-19患者中经历肝功能障碍的安全性和有效性.
- 评估雷梅西维尔对死亡率,不良事件和临床康复时间表的影响.
主要方法:
- 一项回顾性队列研究包括268名COVID-19患者肝酶升高,比较了134名接受雷梅西维尔治疗的患者和134名对照患者.
- 分析的结果包括住院和30天死亡率,不良事件,临床改善时间和出院时间.
- 统计分析采用了逻辑回归,显著性设置在p < 0.05.
主要成果:
- 雷梅西维尔的使用与显著更快的临床康复有关 (调整后β=-2.18天,p=0.035).
- 虽然医院住院死亡率在补救药组 (10.45%对7.46%) 较高,但这种差异在统计学上并不显著 (p=0.109).
- 雷梅西维尔组的严重不良事件几乎翻了一番 (OR 1.90),但这并没有达到统计学意义 (p=0.054).
结论:
- 雷梅西维尔似乎是COVID-19患者肝功能障碍的安全治疗选择.
- 抗病毒药物显著缩短了临床改善的时间,而不会导致死亡率或严重不良事件的统计显著增加.
相关概念视频
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
248
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
248
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
208
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
208
01:29Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143